South Korea · Delayed Price · Currency is KRW Parataxis Korea Company Description
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide.
Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis.
Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade.
The company was formerly known as Bridge Biotherapeutics, Inc. and changed its name to Parataxis Korea, Inc. in August 2025.
The company was founded in 2015 and is headquartered in Seongnam, South Korea.
| Country | South Korea |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 21 |
| CEO | Jeong-Gyu Lee |
Contact Details
Address: C’s Tower Seongnam, 13486 South Korea | |
| Phone | 82 31 8092 3282 |
| Website | bridgebiorx.com |
Stock Details
| Ticker Symbol | 288330 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeong-Gyu Lee | Chief Executive Officer |
| Sujin Agnes Jung | Chief Operating Officer |